Maxwell De Long MS, MechE Genentech
Maxwell De Long MS, MechE Genentech Director and Senior Principal, Individualized Medicines
Max De Long is a Director and Senior Principal CDMO Site Manager in Genentech’s cell and gene therapy organization. He has worked in biopharma for 15 years, and has closely worked domestically and internationally with a host of CDMOs. His experience includes the successful startup and licensure of Samsung Biologics, establishment of the CDMO CMC roadmap for Graphite Bio, and oversight of more than 30 unique contract manufacturing, testing, and development organizations. He values his volunteer experiences, both with industry forums such as PDA, where he is the Vice Chair of the Biopharmaceutical Advisory Board, and with early educational mentorship programs in his local community. Max is an active member of the early career professional community at PDA, and he is always looking for developing talent within the industry.